MAR 12, 2018 12:45 AM PDT

Treating Hearing Loss: A Set of Inhibiting Drugs Provide Promising Results

WRITTEN BY: Nouran Amin

Our inner ears contain roughly 30,000 tiny hair cells that work to detect sound waves as well as to translate these waves into nerve signals. The nerve signals allow us to hear everyday sounds from speeches to music.

However, any damage to the hair cells leads to hearing loss, a condition that affects 48 million Americans. The damage may result from exposure to high amounts of noise, natural aging, as well as some chemotherapeutic drugs and antibiotics. Unfortunately, there are currently no FDA-approved medications that can treat or prevent hearing loss.

Now, a recently published study in the Journal of Experimental Medicine, claims that inhibiting the function of an enzyme known as cyclin-dependent kinase 2 could reverse hearing loss and save millions of affected individuals. Inhibiting cyclin-dependent kinase 2 (CDK2) in model rodents resulted in protecting the hair cells from damage. Since there are no FDA-approved drugs on the market to treat hearing loss, CDK2-inhibiting drug may be a great candidate if proven safe and effective.

The research study originally examined roughly 4,000 drugs that protect hair cells from damaging effects of a chemotherapeutic drug called cisplatin. The study identified compounds that protected cochlear cells from cisplatin, including some that are approved in the treatment of other conditions.

Cisplatin is effective in treating cancer however one of the major side-effects is inducing hearing loss in up to 70% of patients. However, researchers found that induction of hearing loss due to cisplatin is reversible when the screening of drugs found three CDK2 inhibitors that provided the greatest efficacy. The most effective of these CDK2 inhibiting drugs was a compound called “kenpaullone”. The research study identified compounds that provided protection of cochlear cells from cisplatin, several of which are already approved to treat other conditions. Three of the ten most effective compounds were inhibitors of an enzyme called CDK2. One of these CDK2 inhibitors, kenpaullone, was more effective than four other compounds that are currently in clinical trials for treating hearing loss.

Investigators found that injecting kenpaullone into the middle ear of mice blocked CDK2 from processing the production of toxic reactive oxygen species, a damaging biological agent developed from the cells mitochondria. The mice were protected from the adverse effects of cisplatin-related hearing loss when administered with kenpaullone.

Furthermore, the study also found that kenpaullone protected mice from damage due to high decibel noise, preventing hearing loss. "Given that 100-[decibel] noise is in the range of noise insults commonly experienced by people in our society, kenpaullone could have significant clinical application in treating noise-induced hearing loss," says lead researcher, Dr. Jian Zuo.

The research team believes that a single kenpaullone injection may be so powerful to protect hearing, as demonstrated in mice. "The robust protection conferred by one-time local delivery of kenpaullone suggests that CDK2 inhibitors may transform the clinical prevention and treatment of cisplatin- and noise-induced hearing loss in patients," says Dr. Jian Zuo, "Modifications of the treatment regimens, additional optimization of the delivery methods via the use of hydrogels, and structural modifications of the compounds via medicinal chemistry could ensure even better results with CDK2 inhibitors in treating hearing loss in humans”.

Sources: Journal of Experimental Medicine, Medical News Today, Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 27, 2018
Drug Discovery
JUN 27, 2018
Potential Drug May 'Freeze' Cancer Cells
New research study is bringing hope to cancer patients undergoing the early stages of the disease, published in the journal Nature Communications, the stud...
JUL 11, 2018
Drug Discovery
JUL 11, 2018
'Acetazolamide' Used To Treat Altitude Sickness, Slows Down the Development of Glioblastoma
    Acetazolamide, which is sold under the trade name Diamox and used to treat altitude sickness, is considered inexpensive to manufacture and ea...
JUL 31, 2018
Drug Discovery
JUL 31, 2018
Pill Approved For Endometriosis Treatment
A first drug, by the name of Elagolix, to treat for endometriosis-related pain, has recently become approved by the US Food and Drug Administration. Endome...
AUG 01, 2018
Drug Discovery
AUG 01, 2018
Effective Drug For Disorders of Copper Metabolism
According to a paper in the Proceedings of the National Academy of Sciences, a research team led by Dr. Vishal Gohil of Texas A&M AgriLife Research in...
AUG 15, 2018
Drug Discovery
AUG 15, 2018
Peripheral Nerve Blockers Treat Facial Pain
A new research study published American Journal of Emergency Medicine explains the use of peripheral nerve inhibitors in the treatment of facial pain condi...
AUG 27, 2018
Cardiology
AUG 27, 2018
Drug Reduces Deaths and Hospitalization from Heart Failure
New drug reduces deaths and hospitalization rates, while also improving quality of life, for patients with rare type of cardiomyopathy....
Loading Comments...